News Summary

• GLP-1 drugs for weight loss have become a proving ground for a cohort of executives, tech billionaires, and politicians.
• The Trump administration collaborated with manufacturers to create “direct to consumer” pricing for the drugs.
• The administration agreement creates a separate financing track for one type of drug, outside the current health system’s (already inadequate) financial protections for patients.
• The public research funding that made these drugs possible is being slashed.
• Private wealth will have even more influence over the direction of future medical research.